Efikasi pregabalin terhadap perbaikan klinis nyeri pada pasien dengan central post-stroke pain (CPSP): Studi tinjauan sistematis
Mirza Taftazani(1*), Yudiyanta Yudiyanta(2)
(1) KSM Saraf, RSI At-Tin Husada Ngawi
(2) Departemen Neurologi Fakultas Kedokteran, Kesehatan Masyarakat, dan Keperawatan, Universitas Gadjah Mada, Yogyakarta/RSUP Dr Sardjito
(*) Corresponding Author
Abstract
Central post-stroke pain (CPSP) is defined as a condition of central neuropathic pain associated with post-stroke, characterized by pain and sensory disturbance, where the causes of nociceptive, psychogenic, or peripheral pain have been excluded. Pregabalin is a therapeutic choice for patients with CPSP. Pregabalin has a fairly good safety and tolerance as an antiepileptic drug. However, it also shows efficacy in several neuropathic pain conditions caused by CPSP. This study aims to provide evidence of a systematic study of the efficacy of pregabalin on the clinical improvement of pain in patients with CPSP. The systematic review was carried out through a literature search from 2014-2019 using PRISMA reporting guidelines. Search articles through Scopus, ScienceDirect, Cochrane, MEDLINE, and Pubmed. The selection and assessment of the article were carried out by pain consultant and cerebrovascular consultants. Out of 101 journals, only 3 journals were selected that fit the inclusion and exclusion criteria which were then assessed. All three journals show significant clinical improvement of pain in patients with CPSP. The assessment of the three journals based on Grading of Recommendations Assessment, Development and Evaluation (GRADE), stated that pregabalin recommendations has a low to very low efficacy quality in the clinical improvement of pain in patients with CPSP. Pregabalin has potential efficacy for clinical improvement of pain in CPSP patients. Based on recommendations GRADE pregabalin has low to very low efficacy for clinical improvement of pain in patients with CPSP.
ABSTRAK
Central post-stroke pain (CPSP) didefinisikan sebagai kondisi nyeri neuropati sentral yang berkaitan dengan pascastroke, dikarakteristikkan dengan nyeri dan gangguan sensorik, di mana penyebab nyeri nosisepsi, psikogenik, ataupun periferal sudah disingkirkan. Pregabalin merupakan salah satu pilihan terapi pasien dengan CPSP. Pregabalin memiliki keamanan dan toleransi sebagai obat antiepilepsi yang cukup baik, tetapi juga mampu menunjukkan efikasi pada beberapa kondisi nyeri neuropati yang disebabkan oleh CPSP. Artikel ini bertujuan memberikan bukti kajian sistematis mengenai efikasi pregabalin terhadap perbaikan klinis nyeri pasien dengan CPSP. Tinjuan sistematis dilakukan melalui penelusuran kepustakaan dari tahun 2014-2019 menggunakan pedoman pelaporan PRISMA. Penelusuran artikel melalui Scopus, ScienceDirect, Cochrane, MEDLINE, dan Pubmed. Seleksi dan penilaian artikel dilakukan oleh ahli konsultan nyeri dan serebrovaskular. Dari 101 jurnal, hanya 3 jurnal yang sesuai kriteria inklusi dan eksklusi yang kemudian dilakukan penilaian. Ketiga jurnal menunjukkan perbaikan klinis nyeri pasien dengan CPSP yang signifikan. Penilaian ketiga jurnal berdasarkan rekomendasi Grading of Recommendations Assessment, Development and Evaluation (GRADE) menyatakan bahwa pregabalin memiliki kualitas efikasi rendah hingga sangat rendah terhadap perbaikan klinis nyeri pasien dengan CPSP. Pregabalin memiliki potensi efikasi terhadap perbaikan klinis nyeri pasien dengan CPSP, berdasarkan rekomendasi GRADE pregabalin memiliki efikasi yang rendah hingga sangat rendah terhadap perbaikan klinis nyeri pasien dengan CPSP.
Keywords
Full Text:
PDF (Bahasa Indonesia)References
Feigin VL, Krishnamurthi RV, Parmar P, Norrving B, Mensah GA, Bennett DA, et al. Update on the global burden of ischemic and hemorrhagic stroke in 1990-2013: the GBD 2013 study. Neuroepidemiology. 2015;45(3):161-176.
Langhorne P, Stott DJ, Robertson L, MacDonald J, McAlpine C, Dick F, et al. Medical complications after stroke: a multicenter study. Stroke. 2000;31(6):1223-1229.
Klit H, Finnerup NB, Jensen TS. Central post-stroke pain: clinical characteristics, pathophysiology, and management. The Lancet Neurology. 2009;8(9):857-868.
Klit H, Finnerup NB, Andersen G, Jensen TS. Central poststroke pain: a population-based study. Pain. 2011;152(4):818-824.
Kumar B, Kalita J, Kumar G, Misra UK. Central poststroke pain: a review of pathophysiology and treatment. Anesthesia & Analgesia. 2009;108(5):1645-1657.
Şahin-Onat Ş, Ünsal-Delialioğlu S, Kulaklı F, Özel S. The effects of central post-stroke pain on quality of life and depression in patients with stroke. Journal of Physical Therapy Science. 2016;28(1):96-101.
Freeman R, van Seventer R, Murphy T, Sharma U, Young J. Pregabalin rapidly and significantly improves sleep disturbances in chronic pain syndromes and is associated with sleep improvements in healthy volunteers. The Journal of Pain. 2006;7(4):S44.
Hansson P. Post-stroke pain case study: clinical characteristics, therapeutic options and long-term follow-up. European Journal of Neurology. 2004;11:22-30.
Kalita J, Chandra S, Misra UK. Pregabalin and lamotrigine in central poststroke pain: A pilot study. Neurology India. 2017;65(3):506-511.
Higgins JP, Altman DG, Gøtzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
Rahajeng B, Ikawati Z, Andayani TM, Dwiprahasto I. The effect of pregabalin on the quality of life in patients with central poststroke pain. Journal of Young Pharmacists. 2018;10(2):222-225.
Onouchi K, Koga H, Yokoyama K, Yoshiyama T. An openlabel, long-term study examining the safety and tolerability of pregabalin in Japanese patients with central neuropathic pain. Journal of Pain Research. 2014;7:439-447.
Tang SC, Lee LJ, Jeng JS, Hsieh ST, Chiang MC, Yeh SJ, Hsueh HW, Chao CC. Pathophysiology of central poststroke pain: motor cortex disinhibition and its clinical and sensory correlates. Stroke. 2019;50(10):2851-7.
Alles SR, Cain SM, Snutch TP. Pregabalin as a pain therapeutic: beyond calcium channels. Frontiers in cellular neuroscience. 2020;14:83.
DOI: https://doi.org/10.22146/bns.v20i1.103665
Article Metrics
Abstract views : 9 | views : 9Refbacks
- There are currently no refbacks.
Copyright (c) 2025 Berkala NeuroSains
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.